278 related articles for article (PubMed ID: 27538531)
1. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
François C; Rowse GJ; Hewitt LA; Vo P; Hauser RA
BMC Neurol; 2016 Aug; 16(1):143. PubMed ID: 27538531
[TBL] [Abstract][Full Text] [Related]
2. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
Isaacson S; Shill HA; Vernino S; Ziemann A; Rowse GJ
J Parkinsons Dis; 2016 Oct; 6(4):751-759. PubMed ID: 27636856
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
Biaggioni I; Arthur Hewitt L; Rowse GJ; Kaufmann H
BMC Neurol; 2017 May; 17(1):90. PubMed ID: 28494751
[TBL] [Abstract][Full Text] [Related]
4. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
[TBL] [Abstract][Full Text] [Related]
5. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
[TBL] [Abstract][Full Text] [Related]
6. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
Biaggioni I; Freeman R; Mathias CJ; Low P; Hewitt LA; Kaufmann H;
Hypertension; 2015 Jan; 65(1):101-7. PubMed ID: 25350981
[TBL] [Abstract][Full Text] [Related]
7. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Hauser RA; Hewitt LA; Isaacson S
J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
[TBL] [Abstract][Full Text] [Related]
8. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
Keating GM
Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
[TBL] [Abstract][Full Text] [Related]
9. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
Isaacson SH; Skettini J
Vasc Health Risk Manag; 2014; 10():169-76. PubMed ID: 24729712
[TBL] [Abstract][Full Text] [Related]
10. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease.
Hauser RA; Biaggioni I; Hewitt LA; Vernino S
Mov Disord Clin Pract; 2018; 5(6):627-634. PubMed ID: 30637284
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.
White WB; Hauser RA; Rowse GJ; Ziemann A; Hewitt LA
Am J Cardiol; 2017 Apr; 119(7):1111-1115. PubMed ID: 28159196
[TBL] [Abstract][Full Text] [Related]
12. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
Hauser RA; Heritier S; Rowse GJ; Hewitt LA; Isaacson SH
Clin Neuropharmacol; 2016; 39(5):220-6. PubMed ID: 27332626
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
Isaacson S; Vernino S; Ziemann A; Rowse GJ; Kalu U; White WB
J Am Soc Hypertens; 2016 Oct; 10(10):755-762. PubMed ID: 27614923
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
François C; Hauser RA; Aballéa S; Dorey J; Kharitonova E; Hewitt LA
J Med Econ; 2016; 19(5):515-25. PubMed ID: 26710315
[TBL] [Abstract][Full Text] [Related]
15. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Ketter TA; Cucchiaro J; Loebel A
J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
[TBL] [Abstract][Full Text] [Related]
16. Droxidopa in neurogenic orthostatic hypotension.
Kaufmann H; Norcliffe-Kaufmann L; Palma JA
Expert Rev Cardiovasc Ther; 2015; 13(8):875-91. PubMed ID: 26092297
[TBL] [Abstract][Full Text] [Related]
17. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Elgebaly A; Abdelazeim B; Mattar O; Gadelkarim M; Salah R; Negida A
Clin Auton Res; 2016 Jun; 26(3):171-80. PubMed ID: 26951135
[TBL] [Abstract][Full Text] [Related]
19. Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment.
Hauser RA; Favit A; Hewitt LA; Lindsten A; Gorny S; Kymes S; Isaacson SH
Neurol Ther; 2022 Mar; 11(1):459-469. PubMed ID: 35107750
[TBL] [Abstract][Full Text] [Related]
20. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
